Orion PharmaDHA:ORIONPHARM +3.02%71 Current Ratio is 2.06 as of Mar. 2026, which is 0% below its 10-year median of 2.07. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 446 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 69.06% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Orion Pharma's current ratio for the quarter that ended in Mar. 2026 was 2.06.
Orion Pharma has a current ratio of 2.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Orion Pharma's Current Ratio or its related term are showing as below:
DHA:ORIONPHARM'
s Current Ratio Range Over the Past 10 Years
Min: 1.51 Med: 2.07 Max: 4.26
Current: 2.06
During the past 12 years, Orion Pharma's highest Current Ratio was 4.26. The lowest was 1.51. And the median was 2.07.
DHA:ORIONPHARM's Current Ratio is ranked better than 69.06% of 446
companies
in the Utilities - Independent Power Producers industry
Industry Median: 1.36
vs DHA:ORIONPHARM: 2.06
Orion Pharma (DHA:ORIONPHARM) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Orion Pharma Current Ratio Related Terms
Orion Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Current Ratio Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Current Ratio vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Current Ratio of 2.06 as of Mar. 2026. This is near median its historical median of 2.07. Over the past decade, Orion Pharma's Current Ratio has ranged from 1.51 to 4.26. According to the industry distribution chart, Orion Pharma ranks #138 out of 446 companies in the Utilities - Independent Power Producers industry, placing it in the top 30.9%.
Is Orion Pharma's Current Ratio too high?
Orion Pharma's current Current Ratio of 2.06 is near median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 4.26. The Utilities - Independent Power Producers industry median Current Ratio is 1.36. Orion Pharma's value of 2.06 is 51.5% above this industry median. Based on the distribution chart, Orion Pharma ranks #138 out of 446 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Current Ratio compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #138 out of 446 companies for Current Ratio. This puts Orion Pharma in the upper half of its industry. The industry median Current Ratio is 1.36. Orion Pharma's value of 2.06 is 51.5% above this benchmark. Historically, Orion Pharma's own Current Ratio has ranged from 1.51 to 4.26 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 1.36, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for an Utilities - Independent Power Producers company?
The median Current Ratio among Utilities - Independent Power Producers companies is 1.36, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Current Ratio of 2.06 is 51.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Utilities - Independent Power Producers industry, the median Current Ratio is 1.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Current Ratio is 2.06, which is near median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current Current Ratio is 2.06, which is near median its 10-year median of 2.07 and 51.5% above the Utilities - Independent Power Producers industry median of 1.36. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Current Ratio is 2.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Current Ratio: 2.06 (near median its 10-year median of 2.07)
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
Industry Position: 51.5% above the Utilities - Independent Power Producers median (#138 of 446)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
